This document discusses the philosophy that less government is better and that assistance to businesses and banks would eventually help individuals. It states that the campaign is about more than two men or two parties, but is a contest between two philosophies of government.
FibroTest and ActiTest provide accurate non-invasive assessment of fibrosis and activity in patients with chronic hepatitis B. Studies involving over 3,300 hepatitis B patients found FibroTest had standardized accuracy of 0.84 for fibrosis staging compared to 0.90 for liver biopsy. Analysis of discordant cases found biopsy failure accounted for at least half of discrepancies compared to biomarker results. The biomarkers also demonstrated ability to monitor treatment response and predict clinical outcomes in hepatitis B.
This document summarizes McKesson Corporation's presentation at the 2002 Merrill Lynch Healthcare Services Conference. McKesson is the largest healthcare services company, with $46 billion in revenues. It has seen seven consecutive quarters of earnings per share growth above 30% across its pharmaceutical, medical-surgical, and information solutions business units. McKesson aims to continue delivering industry-leading solutions and margin expansion across its business units to create value for customers and shareholders.
This document discusses the philosophy that less government is better and that assistance to businesses and banks would eventually help individuals. It states that the campaign is about more than two men or two parties, but is a contest between two philosophies of government.
FibroTest and ActiTest provide accurate non-invasive assessment of fibrosis and activity in patients with chronic hepatitis B. Studies involving over 3,300 hepatitis B patients found FibroTest had standardized accuracy of 0.84 for fibrosis staging compared to 0.90 for liver biopsy. Analysis of discordant cases found biopsy failure accounted for at least half of discrepancies compared to biomarker results. The biomarkers also demonstrated ability to monitor treatment response and predict clinical outcomes in hepatitis B.
This document summarizes McKesson Corporation's presentation at the 2002 Merrill Lynch Healthcare Services Conference. McKesson is the largest healthcare services company, with $46 billion in revenues. It has seen seven consecutive quarters of earnings per share growth above 30% across its pharmaceutical, medical-surgical, and information solutions business units. McKesson aims to continue delivering industry-leading solutions and margin expansion across its business units to create value for customers and shareholders.